IP Library Granted Patent US 11,339,151
Granted Patent B2
US 11,339,151 · App. 17/528,743 · Granted May 24, 2022

Aliphatic acid amide derivative

Inventors: Yuki Fujii (Tokyo, JP); Masayuki Sakuma (Tokyo, JP); Yoshinori Aihara (Osaka, JP); Jeremy Besnard (United Kingdom, GB); Andrew Simon Bell (United Kingdom, GB)
Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
C07D413/14C07D401/04C07D413/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,339,151
App. No.
17/528,743
Filed
Nov 17, 2021
Granted
May 24, 2022
Kind
B2
Art Unit
1624
USPC
514/254.04
Abstract

The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT 2A receptors and serotonin 5-HT 7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R 1a through R 1d , R 2a through R 2d , and R 4a through R 4d are a hydrogen atom and the like; R 3 is alkyl and the like; and Q is a specific bicyclic group.)

Claims (16)

1. A compound which is represented by any one of the following formulae:

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Jun 3, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 060096/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2021
From: FUJII, YUKI; SAKUMA, MASAYUKI; AIHARA, YOSHINORI; BESNARD, JEREMY; BELL, ANDREW SIMON
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 058141/0234 →
Priority Claims (1)
JP JP2019-232927 · Dec 24, 2019 · national
Continuity (2)
Continuation PCTJP2020048117 · Dec 23, 2020
Related Publication 20220073506A1 · Mar 10, 2022
Cited By (1)
US 12,503,463